Fierce Healthcare December 7, 2022
Teresa Carey

The healthcare industry is grappling with rising drug prices. The expectation is, though, that the wave of biosimilars launching next year will make a dent in healthcare costs. Paige Minemyer interviews Alan Lotvin, M.D., president of CVS Health’s Caremark pharmacy benefit manager, about biosimilars’ potential. 


Today's Sponsors


Today's Sponsor

Health Edge

Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Pfizer and Ada Health Inc. To Launch Nationwide Online COVID-19 Care Journey
Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act

Share This Article